INTELLECTUAL PROPERTY PROTECTION As GBM is an orphan indication,...

INTELLECTUAL PROPERTY PROTECTION As GBM is an orphan indication, paxalisib will also get a minimum of 7 years marketing exclusivity in the US from the data of approval. The key patents on the chemical entity expire in 2030 in the US and 2031 in most other jurisdictions. The key patents relate to the chemical entity and are considered strong IP protection. The expiry on the patents should be around about the same time as the end of the marketing exclusivity. So, according to the report- minimum of 7 to 10 yrs? If approved in 2021 then 9? (9 x 1 billion)... yeah; I can see a bigger fish paying half that out right ..... Is the math wrong? Am I missing something here?